Brief: Bio-Rad Q3 Adjusted EPS USD 2.26 Vs. IBES Estimate USD 1.95
29/10/2025 20:15
Oct 29 (Reuters) - Bio-Rad Q3 gross margin 52.6%. Q3 net income USD -341.9 million Q3 sales USD 653 million vs. IBES estimate USD 651.8 million Q3 EPS USD -12.7 outlook FY adjusted revenue growth 0-1%
Recent news on Bio-Rad Laboratories
See all newsBio-Rad Laboratories, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Bio-Rad Laboratories On July 31, Initiated Restructuring Plan - SEC Filing
Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth
Brief: Bio-Rad Q2 Net Income USD 371.4 Million
Activist investors make bigger push for campaigns in H1, seek more M&A